IMA Medical Group significantly expands the partnership with MedAvail by providing an integrated SpotRx pharmacy experience

IMA Medical Group significantly expands the partnership with MedAvail by providing an integrated SpotRx pharmacy experience

Innovative self-service pharmacy kiosks to be incorporated in 17 additional locations throughout Central Florida

MISSISSAUGA, Ontario and PHOENIX, January 05, 2022– (BUSINESS WIRE) – MedAvail Holdings, Inc. (Nasdaq: MDVL) (“MedAvail”), a pharmaceutical technology company, announced today that it has significantly expanded its partnership with IMA Medical Group, a provider of high quality products primary health and wellness services for seniors, with plans to open 17 additional SpotRx locations in central Florida.

In-clinic SpotRx kiosks and courier home delivery are expected to be available to patients through the IMA network at 21 IMA medical centers, including the four SpotRx locations previously announced in September. MedAvail plans to leverage its pharmacy hub in Orlando to deploy and service SpotRx kiosks at these medical centers and plans to complete rollout in these locations by early 2022. SpotRx Pharmacy is the retail pharmacy brand of owned and operated by MedAvail in the United States, which distributes and operates MedAvail MedCenters.

“We are excited to expand our partnership with IMA and expand the convenience of our transformative pharmaceutical services to Medicare patients in Florida,” said Ed Kilroy, chief executive officer of MedAvail. “We have deployed five of the 17 additional medical centers announced today in the fourth quarter of 2021, with the balance expected to be installed in early 2022.”

MedAvail’s SpotRx Pharmacy business focuses primarily on the Medicare market (65+ years) and the medical clinics where they receive care. The SpotRx MedCenter allows patients to virtually consult a pharmacist and refill their medications within clinics, eliminating the need to visit a pharmacy. SpotRx also offers patients the opportunity to receive medications at home for free.

“After experiencing firsthand the difference in impact our patients had with the integrated SpotRx pharmacies in our clinics, we quickly realized that SpotRx had to be an integral part of our medical centers,” said Dr Mark Leenay, CEO of IMA Medical Group. “We are thrilled to be able to offer this differentiated solution across all of our clinics and further our efforts to provide our patients with the highest standard of care.”

Information on IMA Medical Group

IMA Medical Group provides high quality primary medical and wellness services focusing on improving patient care, reducing costs and providing affordable services for patients, their families and healthcare professionals. Based in Orlando, Florida, IMA serves patients in 23 medical centers across Central Florida including Orlando, Lakeland, Davenport, Winter Haven, Lake Wales, Clermont, Oviedo, Kissimmee, St. Cloud, Debary, Tampa and Town N Country , where over 70 doctors and nurses provide comprehensive medical services to over 40,000 members in partnership with all major Medicare health plans. For more information, visit www.imamedicalgroup.com.

About SpotRx

SpotRx puts control of the pharmacy experience back in the hands of consumers. SpotRx is a telemedicine platform that offers remote pharmacist consultations through an on-site dispensing kiosk, integrated with home delivery capabilities.

About MedAvail

MedAvail Holdings, Inc. (NASDAQ: MDVL) is a technology-enabled pharmaceutical organization, providing turnkey clinic pharmacy services through its proprietary robotic delivery platform, MedAvail MedCenter, and home delivery operations, to Medicare clinics. MedAvail helps patients optimize drug adherence, achieving better health outcomes. Learn more at www.medavail.com.

SOURCE MedAvail Holdings Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220105005452/en/

Contacts

Investor relations
Carolina Paolo
Gilmartin Group
ir@medavail.com

Leave a Comment

Your email address will not be published.